EU Needs OTC Regulatory Overhaul, Automatic Product Approval – AESGP
This article was originally published in The Tan Sheet
Executive Summary
Europe's nonprescription drug industry wants to revamp European Union over-the-counter regulations and open market access by streamlining the product approval process, standardizing advertising rules and extending exclusivity protections
You may also be interested in...
European Switch Progresses, But Stronger Incentives Needed For OTCs
Europe needs to provide more incentives for consumer firms, otherwise the OTC industry will "make commercial decisions" that could reduce their presence in the area, suggested Manfred Scheske, Glaxo-SmithKline's Consumer Healthcare Europe president and VP of the Association of the European Self-Medication Industry, speaking at that organization's meeting in London Jan. 20
European Switch Progresses, But Stronger Incentives Needed For OTCs
Europe needs to provide more incentives for consumer firms, otherwise the OTC industry will "make commercial decisions" that could reduce their presence in the area, suggested Manfred Scheske, Glaxo-SmithKline's Consumer Healthcare Europe president and VP of the Association of the European Self-Medication Industry, speaking at that organization's meeting in London Jan. 20
European Switch Progresses, But Stronger Incentives Needed For OTCs
Europe needs to provide more incentives for consumer firms, otherwise the OTC industry will "make commercial decisions" that could reduce their presence in the area, suggested Manfred Scheske, Glaxo-SmithKline's Consumer Healthcare Europe president and VP of the Association of the European Self-Medication Industry, speaking at that organization's meeting in London Jan. 20